Tasima Lidia J, Hatakeyama Daniela M, Serino-Silva Caroline, Rodrigues Caroline F B, de Lima Eduardo O V, Sant'Anna Sávio S, Grego Kathleen F, de Morais-Zani Karen, Sanz Libia, Calvete Juan J, Tanaka-Azevedo Anita M
Laboratório de Herpetologia, Instituto Butantan, São Paulo, 05503-000, Brazil; Interunidades em Biotecnologia, Instituto de Ciências Biomédicas-Instituto de Pesquisas Tecnológicas-Instituto Butantan, Universidade de São Paulo, 05503-000, Brazil.
Laboratório de Herpetologia, Instituto Butantan, São Paulo, 05503-000, Brazil.
Toxicon. 2020 Oct 15;185:26-35. doi: 10.1016/j.toxicon.2020.07.001. Epub 2020 Jul 4.
The South American rattlesnake Crotalus durissus spp has a wide geographic distribution in Brazil. Although responsible for only a low proportion of ophidian accidents, it is considered one of the most medically important species of venomous snakes due to the high mortality rate (1.87%). Snake venom is a complex phenotype commonly subjected to individual intraspecific, ontogenetic and geographic variability. Compositional differences in pooled venom used in the immunization process may impact the efficacy of the antivenom. In order to assure standardized high-quality antivenom, the potency of each Brazilian crotalic antivenom batch is determined against the 'Brazilian Crotalic Reference Venom' (BCRV). BCRV is produced by Instituto Butantan using venom obtained from the first milking of recently wild-caught C. d. terrificus specimens brought to the Institute. The decrease in the number of snake donations experienced in recent years can become a threat to the production of future batches of BCRV. To evaluate the feasibility of using venom from long-term captive animals in the formulation of BCRV, we have compared the proteomic, biochemical and biological profiles of C. d. terrificus venom pooled from captive specimens (CVP- captive venom pool) and BCRV. Electrophoretic and venomics analyses revealed a very similar venom composition profile, but also certain differences in toxins abundance, with some low abundant protein families found only in BCRV. Enzymatic (L-amino acid oxidase, phospholipase A and proteolytic) and biological (myotoxic and coagulant) activities showed higher values in CVP than in BCRV. CVP also possessed slightly higher lethal effect, although the Instituto Butantan crotalic antivenom showed equivalent potency neutralizing BCRV and CVP. Our results strongly suggest that venom from long-term captive C. d. terrificus might be a valid alternative to generate an immunization mixture of equivalent quality to the currently in use reference venom.
南美响尾蛇(Crotalus durissus spp)在巴西有着广泛的地理分布。尽管它仅导致了低比例的蛇咬伤事故,但由于其高死亡率(1.87%),它被认为是最具医学重要性的毒蛇种类之一。蛇毒是一种复杂的表型,通常存在种内个体、个体发育和地理上的变异性。免疫过程中使用的混合毒液的成分差异可能会影响抗蛇毒血清的疗效。为确保标准化的高质量抗蛇毒血清,每批巴西抗响尾蛇毒血清的效价是针对“巴西响尾蛇参考毒液”(BCRV)测定的。BCRV由布坦坦研究所使用从刚捕获并送至该研究所的野生C. d. terrificus标本首次采得的毒液生产。近年来蛇捐赠数量的减少可能会对未来批次BCRV的生产构成威胁。为评估在BCRV配方中使用长期圈养动物毒液的可行性,我们比较了圈养标本(CVP - 圈养毒液池)和BCRV中C. d. terrificus毒液的蛋白质组学、生化和生物学特征。电泳和毒液组学分析显示毒液成分谱非常相似,但毒素丰度存在某些差异,一些低丰度蛋白家族仅在BCRV中发现。酶活性(L - 氨基酸氧化酶、磷脂酶A和蛋白水解酶)和生物学活性(肌毒性和凝血活性)在CVP中显示的值高于BCRV。CVP也具有略高的致死效应,尽管布坦坦研究所的抗响尾蛇毒血清对BCRV和CVP显示出等效的中和效价。我们的结果强烈表明,长期圈养的C. d. terrificus的毒液可能是一种有效的替代物,可用于生成质量等同于目前使用的参考毒液的免疫混合物。